Drug optimization

Paediatric DTG implementation considerations for national programmes aims to ensure children are transitioned to paediatric dolutegravir safely and effectively, as it provides a range of usage and implementation considerations for national HIV programmes, implementing partners, and service providers.

Paediatric ARV dosing dashboard aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years of age, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who may want to investigate various ARV dosages and calculate the expected drug exposure in children.

2021 dosages for ARV drugs contains information on ARV drugs for which there are paediatric indications, formulations or sufficient information and evidence to provide guidance on prescribing and dosing in infants, children and adolescents under 18. The dosing annex and the simplified dosing schedule will be regularly reviewed and updated as additional data and new formulations become available. (PDF, 601 KB)

Transitioning to the 2021 optimal formulary for antiretroviral drugs for children: implementation considerationsoutlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal antiretroviral medicines and dosage forms become available.

The 2021 optimal formulary and limited-use list for antiretroviral drugs for childrensupports the transition to optimal WHO-recommended ART regimens for infants and children, while giving due consideration to the rapidly evolving treatment landscape and the risks inherent in the uncertain timelines for paediatric drug development.

Considerations for introducing new antiretroviral drug formulations for childrensupports the process of introducing, procuring and scaling up optimal ARV regimens for infants and young children living with HIV in low and middle-income countries.

Policy brief on the new WHO treatment guidelines outlines the anticipated changes for paediatric treatment regimens.

Policy brief "2018 Update of recommendations on first- and second-line antiretroviral regimens" provides the minimum set of products to be made available to deliver the newly recommended regimens across weight bands and different lines of treatment.

Policy brief on transitioning to an optimal paediatric ARV formulary: implementation considerationssupports planning necessary steps to carefully and reliably phase-in and phase-out key products.

New Horizons Disclosure of HIV Status Toolkit for Pediatric and Adolescent Populations provides practical, abbreviated guidance on the process of disclosing an HIV-positive status with pediatric and adolescent populations, their caregivers, partners, and other relevant parties.

New Horizons Management of Treatment Failure for Pediatric and Adolescent Patients Resource Package provides general guidance on determining treatment approaches for pediatric and adolescent patients with a high HIV viral load. - PDF, 1.4 MB